Ensuring Sterility of Parenteral Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ensuring Sterility of Parenteral Products
Experts describe best practices for sterility assurance in parenteral drug manufacturing. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 62-67

References

1. The Local, “Dirty bottle likely source of bacteria in Mainz infant deaths,” Press Release, Aug. 27, 2010.

2. CBS News, “Lethal medicine linked to meningitis outbreak,” Press Release, Mar. 10, 2013.

3. R.P. Vonberg and P. Gastmeier: J. Hosp. Infect., 65 (1) 15-23 (2007).

4. C.M. Clothier, Clothier Report, Report of the Committee appointed to inquire into the circumstances, including the production, which led to the use of contaminated fluids in the Devonport section of Plymouth General Hospital, London: Her Majesty’s Stationery Office, 1972.

5. M.A. Kainer et al, N Engl J Med., 367 (23) 2194-2203 (2012).

6. B. Cox, A Lesson on Outsourcing: The NECC Fungal Meningitis Outbreak, The Gold Sheet, 46 (11) 1-6 (2012).

7. J.S. Eglovitch, Lack of Microbiological Controls Have Grave Consequences for Compounders, The Gold Sheet, 46 (11) 16-18 (2012).

8. B. Verjans and C. Reed, Biopharm. Intl., 25 (3) 46-58 (2012).

9. S.V.W. Sutton, J of GXP Compliance, 16 (4) 59-63 (2012).

10. D. Niccum and P. Hairston in Environmental Monitoring: A Comprehensive Handbook, Volume 6, Jeanne Moldenhauer, Ed. (PDA, Bethesda, MD 20814, 2012), pp. 219-240.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here